# US 2024/0189412 A1 · Zika Virus Polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189412 A1
- Document ID: US20240189412A1
- Status: Published application
- Kind: A1
- Application number: 17/908,704
- Filed: 2021-03-01
- Published: 2024-06-13
- Earliest claimed: 2020-03-03
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Gregory A. POLAND; Inna G. OVSYANNIKOVA; Richard B. KENNEDY
- Web page: https://patentgrep.com/patent/US20240189412A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/572: {cytotoxic response}
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This document provides methods and materials related to selected Zika virus polypeptides. For example. vaccine compositions that contain one or more selected Zika virus polypeptides provided herein and that have the ability to increase immune responses against flaviviruses such as Zika viruses within a mammal (e.g., a human) are provided.

## Claims

### Claim 1

A substantially pure polypeptide consisting essentially of or consisting of the amino acid sequence set forth in any one of SEQ ID NOs:1-17.

### Claim 2 (depends on 1)

The substantially pure polypeptide of claim 1, wherein said polypeptide is covalently conjugated to a stabilizer selected from the group consisting of sucrose, lactose, a monosodium salt of glutamic acid, human serum albumin, and gelatin.

### Claim 3

A composition comprising at least four polypeptides, wherein each of said at least four polypeptides is a polypeptide consisting essentially of or consisting of the amino acid sequence set forth in any one of SEQ ID NOs:1-17.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said each of said at least four polypeptides is a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOs:1-17.

### Claim 5 (depends on 3)

The composition of claim 3, wherein said each of said at least four polypeptides is a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOs:1-9.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1-5, wherein said composition comprises a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:3, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:5, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:6, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:7, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:7, and a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:9.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1-6, wherein said composition comprises an adjuvant.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said adjuvant is selected from the group consisting of a CpG oligonucleotide motif, aluminum sulfate, aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate, monophosphoryl lipid A, aluminumphosphylate, MF59, AS03, and AS04.

### Claim 9

A method for increasing an immune response against a flavivirus in a mammal, wherein said method comprises administering to said mammal a composition comprising a polypeptide consisting essentially of or consisting of the amino acid sequence set forth in any one of SEQ ID NOs:1-17.

### Claim 10 (depends on 9)

The method of claim 9, wherein said mammal is a human.

### Claim 11 (depends on 9, 10)

The method of any one of claims 9-10, wherein said flavivirus is a Zika virus.

### Claim 12 (depends on 9, 10, 11)

The method of any one of claims 9-11, wherein said composition comprises an adjuvant.

### Claim 13 (depends on 12)

The method of claim 12, wherein said adjuvant is selected from the group consisting of a CpG oligonucleotide motif, aluminum sulfate, aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate, monophosphoryl lipid A, aluminumphosphylate, MF59, AS03, and AS04.

### Claim 14 (depends on 9, 10, 11, 12, 13)

The method of any one of claims 9-13, wherein said composition comprises at least four polypeptides, wherein each of said at least four polypeptides is a polypeptide consisting essentially of or consisting of the amino acid sequence set forth in any one of SEQ ID NOs:1-17.

### Claim 15 (depends on 14)

The method of claim 14, wherein said each of said at least four polypeptides is a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOs:1-17.

### Claim 16 (depends on 14)

The method of claim 14, wherein said each of said at least four polypeptides is a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID NOs:1-9.

### Claim 17 (depends on 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 9-16, wherein said composition comprises a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:3, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:5, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:6, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:7, a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:7, and a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:9.